Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute lymphoblastic leukemia in adults: recent progress, future directions.

D Hoelzer, R P Gale

    Seminars in Hematology
    |January 1, 1987
    PubMed
    Summary

    Recent advancements in adult acute lymphoblastic leukemia (ALL) treatment show high remission rates with induction chemotherapy. Consolidation/intensification therapy improves long-term survival, and defined risk groups guide future therapeutic strategies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia.

    Annals of oncology : official journal of the European Society for Medical Oncology·2023
    Same author

    Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.

    Blood cancer journal·2016
    Same author

    Prof. Thomas Büchner (22 September 1934-5 August 2016)-A leading European hematologist and AML trialist.

    Leukemia·2016
    Same author

    Detection of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia by Analysis of Gene Rearrangements and Correlation with Early Relapses.

    Leukemia & lymphoma·2016
    Same author

    Change in prognostic factors.

    Leukemia supplements·2016
    Same author

    Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    Annals of oncology : official journal of the European Society for Medical Oncology·2016

    Area of Science:

    • Hematology
    • Oncology
    • Clinical Medicine

    Background:

    • Adult acute lymphoblastic leukemia (ALL) remains a significant hematologic malignancy.
    • Substantial progress has been made in improving treatment outcomes for adult ALL patients.

    Purpose of the Study:

    • To review recent advancements in the treatment of adult ALL.
    • To evaluate the efficacy of different therapeutic strategies and identify prognostic factors.

    Main Methods:

    • Review of existing data on adult ALL treatment regimens.
    • Analysis of remission rates, remission duration, and disease-free survival.
    • Identification and evaluation of prognostic factors for risk stratification.

    Main Results:

    Related Experiment Videos

    • Induction chemotherapy achieves remission in 70-80% of adult ALL patients.
    • Consolidation/intensification therapy is associated with the longest remissions and improved disease-free survival (35-45% at 5 years).
    • Defined prognostic factors (age, WBC, immunologic subtype, cytogenetics) allow stratification into low-risk (≥60% DFS) and high-risk (20-25% DFS) groups.

    Conclusions:

    • Current induction chemotherapy is effective for achieving remission in adult ALL.
    • Consolidation/intensification strategies are crucial for improving long-term outcomes.
    • Risk stratification based on defined prognostic factors is essential for tailoring future therapeutic approaches in adult ALL.